Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

P-1959. Duration and Quantification of Histoplasma capsulatum Antigenuria During Treatment of Histoplasmosis in Patients by Immune Status

Title: P-1959. Duration and Quantification of Histoplasma capsulatum Antigenuria During Treatment of Histoplasmosis in Patients by Immune Status
Authors: Fallon, Samuel M; Zuniga-Moya, Julio C; Mazi, Patrick B; Rauseo, Adriana; Spec, Andrej
Source: Open Forum Infectious Diseases ; volume 13, issue Supplement_1 ; ISSN 2328-8957
Publisher Information: Oxford University Press (OUP)
Publication Year: 2026
Description: Background Despite its classic association with HIV, modern cohorts of histoplasmosis are overwhelmingly in those with non-HIV-associated immunocompromise, such as biologic immunosuppression or solid organ transplantation. However, treatment guidelines are largely extrapolated from 30-year-old studies of patients with HIV. Methods We conducted a single-center, retrospective study of adult patients with varying immune status diagnosed with histoplasmosis by positive antigen testing and undergoing treatment between 2002 to 2021. Time to H. capsulatum antigen negativity was calculated and compared between immune status groups using competing risk analysis. Per-patient, mean antigen levels were compared at 6mo intervals from diagnosis. Results 95 patients treated for histoplasmosis had varying immunocompromise: immunocompetent (n=21), biologic immunosuppression (n=18), people living with HIV (PLWH) (n=18), any transplant (n=28), and other (n=10) – primarily prednisone with methotrexate or other disease modifying therapy (7/10). Median time to antigen negativity, accounting for competing risk of death by group was: transplant - 22.7mo, PLWH - 16.9mo, biologics - 12.9mo, other immunocompromise - 13.2mo, and immunocompetent - 6.8mo (Figure 1). Median antigen level at diagnosis was highest in PLWH (20ng/mL [Q1: 13.5, Q3: 20]) and transplant patients (9.2ng/mL [4.1, 15.9]) versus the other groups – immunocompetent: (2.4ng/mL [0.5, 6.0]), biologics: (2.8ng/mL [2.0, 4.9]), other: (3.1ng/mL [1.6, 15.6]) (Figures 2 & 3). Of patients not deceased or lost to follow-up at 24mo, 31.6% (6/19) of transplant patients and 28.6% (4/14) of biologic patients had positive antigen testing versus 0% (0/7) of PLWH, 6.2% (1/16) of immunocompetent patients and 20% (1/5) of other immunocompromise patients. Conclusion Median time to antigen negativity was highest in transplant patients and PLWH and intermediate in biologic and other immunocompromise groups relative to immunocompetent patients. More than 80% of patients with ...
Document Type: article in journal/newspaper
Language: English
DOI: 10.1093/ofid/ofaf695.2126
Availability: https://doi.org/10.1093/ofid/ofaf695.2126; https://academic.oup.com/ofid/article-pdf/13/Supplement_1/ofaf695.2126/66356517/ofaf695.2126.pdf
Rights: https://creativecommons.org/licenses/by/4.0/
Accession Number: edsbas.DB0EFE9
Database: BASE